(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual revenue growth rate of 48.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Vistagen Therapeutics's revenue in 2024 is $1,042,300.On average, 3 Wall Street analysts forecast VTGN's revenue for 2024 to be $30,430,385, with the lowest VTGN revenue forecast at $24,322,688, and the highest VTGN revenue forecast at $34,592,268. On average, 2 Wall Street analysts forecast VTGN's revenue for 2025 to be $10,945,210, with the lowest VTGN revenue forecast at $10,810,084, and the highest VTGN revenue forecast at $11,080,336.
In 2027, VTGN is forecast to generate $135,126,045 in revenue, with the lowest revenue forecast at $135,126,045 and the highest revenue forecast at $135,126,045.